Miguel Gil‐Gil - Concepedia

Author

Miguel Gil‐Gil

Also Known As

Gil-Gil, Miguel J, J. Gil-Gil, J.M. Gil Gil, Juan Miguel Gil-Gil, M Gil, M Gil-Gil, M M Keane, M. Gil, M. Gil Gil, M. Gil-Gil

504

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Institut Català d'Oncologia Institut d'Investigació Biomédica de Bellvitge Bellvitge University Hospital Hospital Universitari Germans Trias i Pujol Hospital Universitario Virgen del Rocío

About

Miguel Gil‐Gil is an author at Institut Català d'Oncologia specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	1.9K
2	Health Sciences	6	6	145
3	Engineering	1	1	43
4	Cell Biology	1	1	42
5	Clinical Nutrition	1	1	11

Miguel Gil‐Gil

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi, William Jacot, Toshinari Yamashita, New England Journal of Medicine	2022	2.3K
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial Robert E. Coleman, David Cameron, David Dodwell, The Lancet Oncology Breast OncologyEarly Breast CancerMedicineCancer ManagementPharmacology	2014	290
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study Erica L. Mayer, Amylou C. Dueck, Miguel Martín, The Lancet Oncology Interim AnalysisEndocrine OncologyBreast OncologyOncologyEarly Breast Cancer	2021	250
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial E. Verger, Miguel Gil‐Gil, Ricardo Yayá, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyPhase IiRadiation TherapyBrain MetastasesMedicine	2004	210
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial Aleix Prat, Cristina Saura, Tomás Pascual, The Lancet Oncology Breast OncologyMedicinePharmacologyGynecologyBreast Cancer	2019	191
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, Annals of Oncology	2020	130
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma David A. Reardon, G. Dresemann, Sophie Taillibert, British Journal of Cancer	2009	128
Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz Salgado, Carmen Balañá, Neuro-Oncology	2017	119
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer Robert E. Coleman, Emma R. Woodward, Janet E. Brown, Breast Cancer Research and Treatment Bone DiseaseZoledronic AcidBreast OncologyOncologyBone Health	2011	118
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01) Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez, Neuro-Oncology	2020	103

Page 1